Abera Bioscience operates in biotechnology. The company specializes in the development of vaccines based on a proprietary and patented platform. The technology is mainly used in the development of new vaccines, with a focus on the main areas of pneumococci and immuno-oncology. The operations are located throughout the Nordic market. The company was founded in 2012 and is headquartered in Solna.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Pension | 11,57 | 11,57 | 2025-12-23 |
| Göran Ofsén | 9,61 | 9,61 | 2026-01-30 |
| Nordnet Pensionsförsäkring | 7,25 | 7,25 | 2025-12-23 |
| Anders Ericsson | 3,38 | 3,38 | 2025-12-23 |
| Jan-Willem De Gier | 3,22 | 3,22 | 2025-12-23 |
| Joen Luirink | 3,16 | 3,16 | 2025-12-23 |
| Stefan Olsson | 2,93 | 2,93 | 2025-12-23 |
| Maths Wahlström | 2,71 | 2,71 | 2025-12-23 |
| Agneta Albinsson | 2,71 | 2,71 | 2025-12-23 |
| Anders Wall stiftelser | 2,00 | 2,00 | 2025-12-23 |
2026-05-12 Interim Report 2026-Q1
2026-06-10 Annual General Meeting 2025
2026-08-20 Interim Report 2026-Q2
2026-11-17 Interim Report 2026-Q3
2027-02-15 Year End Report 2026